These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8614273)

  • 1. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease.
    Sramek JJ; Anand R; Wardle TS; Irwin P; Hartman RD; Cutler NR
    Life Sci; 1996; 58(15):1201-7. PubMed ID: 8614273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.
    Cutler NR; Polinsky RJ; Sramek JJ; Enz A; Jhee SS; Mancione L; Hourani J; Zolnouni P
    Acta Neurol Scand; 1998 Apr; 97(4):244-50. PubMed ID: 9576639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).
    Forette F; Anand R; Gharabawi G
    Eur J Neurol; 1999 Jul; 6(4):423-9. PubMed ID: 10362894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
    Rösler M; Anand R; Cicin-Sain A; Gauthier S; Agid Y; Dal-Bianco P; Stähelin HB; Hartman R; Gharabawi M
    BMJ; 1999 Mar; 318(7184):633-8. PubMed ID: 10066203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivastigmine. A review of its use in Alzheimer's disease.
    Spencer CM; Noble S
    Drugs Aging; 1998 Nov; 13(5):391-411. PubMed ID: 9829166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.
    Farlow M; Anand R; Messina J; Hartman R; Veach J
    Eur Neurol; 2000; 44(4):236-41. PubMed ID: 11096224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.
    Feldman HH; Lane R;
    J Neurol Neurosurg Psychiatry; 2007 Oct; 78(10):1056-63. PubMed ID: 17353259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First clinical evaluation of ganstigmine in patients with probable Alzheimer's disease.
    Jhee SS; Fabbri L; Piccinno A; Monici P; Moran S; Zarotsky V; Tan EY; Frackiewicz EJ; Shiovitz T
    Clin Neuropharmacol; 2003; 26(3):164-9. PubMed ID: 12782920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine.
    Jhee SS; Shiovitz T; Hartman RD; Messina J; Anand R; Sramek J; Cutler NR
    Clin Neuropharmacol; 2002; 25(2):122-3. PubMed ID: 11981242
    [No Abstract]   [Full Text] [Related]  

  • 11. Rivastigmine for Alzheimer's disease.
    Birks J; Iakovidou V; Tsolaki M
    Cochrane Database Syst Rev; 2000; (2):CD001191. PubMed ID: 10796621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase.
    Sramek JJ; Block GA; Reines SA; Sawin SF; Barchowsky A; Cutler NR
    Life Sci; 1995; 56(5):319-26. PubMed ID: 7837931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption, metabolism, and disposition of [14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration.
    Tse FL; Laplanche R
    Pharm Res; 1998 Oct; 15(10):1614-20. PubMed ID: 9794506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.
    Bilikiewicz A; Opala G; Podemski R; Puzyński S; Łapin J; Sołtys K; Ochudło S; Barcikowska M; Pfeffer A; Bilińska M; Paradowski B; Parnowski T; Gabryelewicz T
    Med Sci Monit; 2002 Feb; 8(2):PI9-15. PubMed ID: 11859291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrocardiographic effects of rivastigmine.
    Morganroth J; Graham S; Hartman R; Anand R
    J Clin Pharmacol; 2002 May; 42(5):558-68. PubMed ID: 12017350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor.
    Enz A; Boddeke H; Gray J; Spiegel R
    Ann N Y Acad Sci; 1991; 640():272-5. PubMed ID: 1776750
    [No Abstract]   [Full Text] [Related]  

  • 17. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.
    Cummings JL; Farlow MR; Meng X; Tekin S; Olin JT
    Clin Drug Investig; 2010; 30(1):41-9. PubMed ID: 19995097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivastigmine for vascular cognitive impairment.
    Birks J; McGuinness B; Craig D
    Cochrane Database Syst Rev; 2013 May; (5):CD004744. PubMed ID: 23728651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders.
    Desai A; Grossberg G
    Expert Opin Pharmacother; 2001 Apr; 2(4):653-66. PubMed ID: 11336614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
    Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
    Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.